GENOCEA BIOSCIENCES, INC.
GENOCEA BIOSCIENCES, INC. (GNCA): 2 pipeline candidates · ~4 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.3 months
D/E 2.13 · 21% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for GENOCEA BIOSCIENCES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$20.8M
Quarterly Burn
$15.2M
Runway
4.3 mo
Revenue
$270K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in GENOCEA BIOSCIENCES, INC.'s pipeline?
GENOCEA BIOSCIENCES, INC. (GNCA) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GENOCEA BIOSCIENCES, INC.'s lead drug candidate?
GENOCEA BIOSCIENCES, INC.'s most advanced tracked candidate is gen-009 (Phase 2) for Solid tumors.
What is GENOCEA BIOSCIENCES, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GENOCEA BIOSCIENCES, INC. has approximately 4.3 months of cash runway.
Who is the CEO of GENOCEA BIOSCIENCES, INC.?
William Clark is the chief executive officer of GENOCEA BIOSCIENCES, INC. (GNCA).
Get the full picture on GENOCEA BIOSCIENCES, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.